Regulus Therapeutics, a clinical stage biopharmaceutical company headquartered in San Diego, California, is spearheading the discovery and development of drugs that target microRNAs to treat a range of diseases within the United States. Currently, the company has two product candidates in the works: RG-012, an anti-miR targeting miR-21, which is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease, and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. Moreover, Regulus Therapeutics is developing a pipeline of preclinical drug products for target organ-selective delivery strategies. The company was incorporated in 2007 and has been at the forefront of drug development with its innovative approach.